Cargando…
Updated Insights on EGFR Signaling Pathways in Glioma
Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827907/ https://www.ncbi.nlm.nih.gov/pubmed/33435537 http://dx.doi.org/10.3390/ijms22020587 |
_version_ | 1783640881521229824 |
---|---|
author | Oprita, Alexandru Baloi, Stefania-Carina Staicu, Georgiana-Adeline Alexandru, Oana Tache, Daniela Elise Danoiu, Suzana Micu, Elena Simona Sevastre, Ani-Simona |
author_facet | Oprita, Alexandru Baloi, Stefania-Carina Staicu, Georgiana-Adeline Alexandru, Oana Tache, Daniela Elise Danoiu, Suzana Micu, Elena Simona Sevastre, Ani-Simona |
author_sort | Oprita, Alexandru |
collection | PubMed |
description | Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor, new diagnosis and treatment strategies are needed. Due to the quick progression, even with aggressive multimodal treatment, glioblastoma remains almost incurable. It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit. Many factors contribute to resistance, such as ineffective blood–brain barrier penetration, heterogeneity, mutations, as well as compensatory signaling pathways. A better understanding of the EGFR signaling network, and its interrelations with other pathways, are essential to clarify the mechanisms of resistance and create better therapeutic agents. |
format | Online Article Text |
id | pubmed-7827907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78279072021-01-25 Updated Insights on EGFR Signaling Pathways in Glioma Oprita, Alexandru Baloi, Stefania-Carina Staicu, Georgiana-Adeline Alexandru, Oana Tache, Daniela Elise Danoiu, Suzana Micu, Elena Simona Sevastre, Ani-Simona Int J Mol Sci Review Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor, new diagnosis and treatment strategies are needed. Due to the quick progression, even with aggressive multimodal treatment, glioblastoma remains almost incurable. It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit. Many factors contribute to resistance, such as ineffective blood–brain barrier penetration, heterogeneity, mutations, as well as compensatory signaling pathways. A better understanding of the EGFR signaling network, and its interrelations with other pathways, are essential to clarify the mechanisms of resistance and create better therapeutic agents. MDPI 2021-01-08 /pmc/articles/PMC7827907/ /pubmed/33435537 http://dx.doi.org/10.3390/ijms22020587 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Oprita, Alexandru Baloi, Stefania-Carina Staicu, Georgiana-Adeline Alexandru, Oana Tache, Daniela Elise Danoiu, Suzana Micu, Elena Simona Sevastre, Ani-Simona Updated Insights on EGFR Signaling Pathways in Glioma |
title | Updated Insights on EGFR Signaling Pathways in Glioma |
title_full | Updated Insights on EGFR Signaling Pathways in Glioma |
title_fullStr | Updated Insights on EGFR Signaling Pathways in Glioma |
title_full_unstemmed | Updated Insights on EGFR Signaling Pathways in Glioma |
title_short | Updated Insights on EGFR Signaling Pathways in Glioma |
title_sort | updated insights on egfr signaling pathways in glioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827907/ https://www.ncbi.nlm.nih.gov/pubmed/33435537 http://dx.doi.org/10.3390/ijms22020587 |
work_keys_str_mv | AT opritaalexandru updatedinsightsonegfrsignalingpathwaysinglioma AT baloistefaniacarina updatedinsightsonegfrsignalingpathwaysinglioma AT staicugeorgianaadeline updatedinsightsonegfrsignalingpathwaysinglioma AT alexandruoana updatedinsightsonegfrsignalingpathwaysinglioma AT tachedanielaelise updatedinsightsonegfrsignalingpathwaysinglioma AT danoiusuzana updatedinsightsonegfrsignalingpathwaysinglioma AT micuelenasimona updatedinsightsonegfrsignalingpathwaysinglioma AT sevastreanisimona updatedinsightsonegfrsignalingpathwaysinglioma |